３－（１－｛３－〔５－（１－甲基－六氫吡啶－４－基甲氧基）－嘧啶－２－基〕－苄基｝－６－酮基－１，６－二氫－噠嗪－３

发明人:: BECKER, AXEL,贝克　艾西尔,貝克　艾西爾,KUEHN, CLEMENS,可汉　克雷曼,可漢　克雷曼,SAAL, CHRISTOPH,赛尔　克里斯多夫,賽爾　克里斯多夫,SCHADT, OLIVER,史其德　奥利佛,史其德　奧利佛,DORSCH, DIETER,朵齐　狄亚特,朵齊　狄亞特,BOKEL, HEINZ-HERMANN,布克　海斯　贺曼,布克　海斯　賀曼,STIEBER, FR,贝克艾西尔,貝克艾西爾,可汉克雷曼,可漢克雷曼,赛尔克里斯多夫,賽爾克里斯多夫,史其德奥利佛,史其德奧利佛,朵齐狄亚特,朵齊狄亞特,布克海斯贺曼,布克海斯賀曼

摘要：: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.本發明係關於一種3-(1-{3-[5-(1-甲基-六氫吡啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-酮基-1,6-二氫-噠嗪-3-基)-苯甲腈氫氯酸鹽溶劑合物及其結晶變體。本發明進一步係關於製備該等結晶變體之方法及其在治療及/或預防生理學及/或病理生理學病狀中之用途，該等病狀係由激酶信號轉導之抑制、調控及/或調節(尤其由酪胺酸激酶之抑制)所導致、介導及/或傳播，例如病理生理學病狀，如：癌症。